Creator Post Archive
Investing Portfolio Pathway
Browse the full post archive, then jump into the source post to inspect linked mentions and linked signals.
Apr 15, 2026
UnitedHealth $UNH Stock Review April 2026
The creator analyzes UnitedHealth Group (UNH) using seasonality, valuation, and technical indicators, noting its historical outperformance in midterm election years despite recent challenges. The analysis suggests a favorable risk-reward profile with potential upside, supported by a low beta, dividend growth, and analyst price targets, leading to a recent re-entry into the stock.
Apr 15, 2026
Lowe's $LOW Stock Review 8 Apr 2026
The creator analyzes Lowe's stock ($LOW), noting its recent price action, technical indicators, and fundamental data. While short-term charts show some bullish signals and positive money flow on a weekly basis, longer-term indicators and distribution patterns suggest caution. The stock is currently in correction territory, trading below its 50-day and 200-day moving averages.
Apr 15, 2026
Citi $C Q1 2026 Earnings Preview
The creator provides an in-depth earnings preview for Citigroup (C), highlighting its transition from a sprawling financial supermarket to a focused institutional powerhouse. The analysis covers current price action, valuation metrics, analyst estimates, and future catalysts like the upcoming investor day, suggesting a positive outlook with significant upside potential.
Apr 15, 2026
Meta $META - Buying the Dip?
The creator discusses Meta ($META), highlighting its recent stock performance, strong fundamentals, and potential in the AI era. Despite legal setbacks, the stock shows significant revenue growth and profit margins. The creator, who owns Meta shares, views the current market price as a discount for a superb business, though acknowledges the need for a strong AI moment. Another analyst discusses selling Meta at $598 due to a head and shoulders pattern and buying back in at lower levels, citing price action over news.
Mar 15, 2026
CorMedix $CRMD Q4 2025 Earnings Preview
CorMedix (CRMD) is set to report Q4 2025 earnings, a critical event following a recent guidance reset. The company, focused on infectious diseases with its product Defencath and a diversified portfolio from the Melinta acquisition, faces scrutiny on its 2027 rebound strategy and buyback program. Analysts remain largely positive, with a consensus strong buy rating and a target price significantly above the current trading level, despite recent analyst estimate revisions and a high short interest.
Mar 15, 2026
Nvidia $NVDA Q4 2025 Earnings Preview
This video provides an in-depth earnings preview for Nvidia (NVDA), covering its Q4 2025 expectations, current price action, valuation metrics, and the creator's personal portfolio holdings. The analysis highlights Nvidia's dominant position in AI infrastructure, its strong financial performance, and positive analyst ratings, suggesting a bullish outlook despite some insider selling and market concerns.
Showing 76-81 of 81 posts · Page 4 of 4